Free Trial
NASDAQ:LXEO

Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Lexeo Therapeutics logo
$4.90 +0.12 (+2.51%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$4.90 +0.00 (+0.02%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lexeo Therapeutics Stock (NASDAQ:LXEO)

Key Stats

Today's Range
$4.80
$5.11
50-Day Range
$3.67
$4.92
52-Week Range
$1.45
$12.37
Volume
519,073 shs
Average Volume
392,470 shs
Market Capitalization
$264.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33
Consensus Rating
Buy

Company Overview

Lexeo Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

LXEO MarketRank™: 

Lexeo Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 594th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lexeo Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Lexeo Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lexeo Therapeutics are expected to grow in the coming year, from ($3.14) to ($2.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lexeo Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lexeo Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lexeo Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    22.93% of the float of Lexeo Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexeo Therapeutics has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Lexeo Therapeutics has recently increased by 1.35%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Lexeo Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lexeo Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.93% of the float of Lexeo Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexeo Therapeutics has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Lexeo Therapeutics has recently increased by 1.35%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Lexeo Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Lexeo Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for LXEO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,696.00 in company stock.

  • Percentage Held by Insiders

    Only 5.30% of the stock of Lexeo Therapeutics is held by insiders.

  • Percentage Held by Institutions

    60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lexeo Therapeutics' insider trading history.
Receive LXEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LXEO Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Headlines

LXEO Stock Analysis - Frequently Asked Questions

Lexeo Therapeutics' stock was trading at $6.58 at the beginning of 2025. Since then, LXEO stock has decreased by 25.5% and is now trading at $4.90.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.04.

Lexeo Therapeutics (LXEO) raised $100 million in an IPO on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $11.00 per share.

Lexeo Therapeutics' top institutional investors include Frazier Life Sciences Management L.P. (13.33%), Balyasny Asset Management L.P. (12.08%), Affinity Asset Advisors LLC (10.81%) and Vestal Point Capital LP (9.72%). Insiders that own company stock include Fund Vi LP Omega, Richard Nolan Townsend, Eric Adler, Jose Manuel Otero and Tai Sandi See.
View institutional ownership trends
.

Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
8/14/2025
Today
8/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LXEO
Previous Symbol
NASDAQ:LXEO
CIK
1907108
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$9.00
Potential Upside/Downside
+212.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$98.33 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-94.65%
Return on Assets
-73.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.43
Quick Ratio
3.42

Sales & Book Value

Annual Sales
$650 thousand
Price / Sales
407.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.56 per share
Price / Book
1.91

Miscellaneous

Outstanding Shares
54,000,000
Free Float
51,139,000
Market Cap
$264.60 million
Optionable
Not Optionable
Beta
1.36
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:LXEO) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners